NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS)
$0.20048 0.01338 (7.1513%)
Analysed NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS) News Sources
Northwest Biotherapeutics: Q2 Earnings Snapshot
14-08-2025
yahoo.com
Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
18-08-2025
yahoo.com
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
27-08-2025
yahoo.com
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
24-10-2025
yahoo.com
Northwest Biotherapeutics: Q3 Earnings Snapshot
14-11-2025
yahoo.com
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
20-11-2025
yahoo.com
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
21-04-2026
yahoo.com
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
30-04-2026
yahoo.com
What is the current price of NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS)?
The current price of NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS) is $0.20048.
NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS) absolute price change since previous trading day?
The absolute price change of NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS) since the previous trading day is $0.01338.
NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS) percentage price change since previous trading day?
The percentage price change of NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS) since the previous trading day is 7.1513%.
What is the most recent average sentiment score for NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS)?
The most recent average sentiment score for NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS) is 44 out of 100.
What is the most recent average sentiment for NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS)?
The most recent sentiment for NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS) is .
SEC-8K** Filing Available For NORTHWEST BIOTHERAPEUTICS (NWBO:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.